Ting Yu1, Yurong Tang1, Liuqin Jiang1, Yongping Zheng1, Wenjie Xiong1, Lin Lin2. 1. Department of Gastroenterology, First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, Jiangsu Province, China. 2. Department of Gastroenterology, First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, Jiangsu Province, China. Electronic address: linlin9100@aliyun.com.
Abstract
BACKGROUND: Previous meta-analyses reported proton pump inhibitor (PPI) therapy is associated with increased incidence of spontaneous bacterial peritonitis (SBP) in cirrhotic patients. However, this conclusion was based on case-control studies. Moreover, the association between PPI use and mortality of SBP has not yet been confirmed. AIMS: To evaluate the association between PPI use and SBP incidence and mortality using case-control and cohort studies. METHODS: We searched Medline, Embase and Web of Knowledge for relevant articles published up to January 2015. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated using a random-effects model. RESULTS: A total of 10 case-control and six cohort studies involving 8145 patients were analyzed. The overall analysis indicated that PPI use was associated with SBP (OR=2.11, 95% CI: 1.46-3.06). The association was limited in case-control studies (OR=2.97, 95% CI: 2.06-4.26) but not in cohort studies (OR=1.18, 95% CI: 0.99-1.14). PPI therapy was not associated with mortality during hospitalization or within 30 days after SBP (OR=1.54, 95% CI: 0.92-2.59). CONCLUSIONS: We could not establish causality that PPI use increases the incidence or mortality of SBP.
BACKGROUND: Previous meta-analyses reported proton pump inhibitor (PPI) therapy is associated with increased incidence of spontaneous bacterial peritonitis (SBP) in cirrhotic patients. However, this conclusion was based on case-control studies. Moreover, the association between PPI use and mortality of SBP has not yet been confirmed. AIMS: To evaluate the association between PPI use and SBP incidence and mortality using case-control and cohort studies. METHODS: We searched Medline, Embase and Web of Knowledge for relevant articles published up to January 2015. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated using a random-effects model. RESULTS: A total of 10 case-control and six cohort studies involving 8145 patients were analyzed. The overall analysis indicated that PPI use was associated with SBP (OR=2.11, 95% CI: 1.46-3.06). The association was limited in case-control studies (OR=2.97, 95% CI: 2.06-4.26) but not in cohort studies (OR=1.18, 95% CI: 0.99-1.14). PPI therapy was not associated with mortality during hospitalization or within 30 days after SBP (OR=1.54, 95% CI: 0.92-2.59). CONCLUSIONS: We could not establish causality that PPI use increases the incidence or mortality of SBP.
Authors: Philip O Katz; Kerry B Dunbar; Felice H Schnoll-Sussman; Katarina B Greer; Rena Yadlapati; Stuart Jon Spechler Journal: Am J Gastroenterol Date: 2022-01-01 Impact factor: 10.864
Authors: Seong Jun Hwang; Dong Hyeon Lee; Seong-Joon Koh; Ji Won Kim; Hyun Sun Park; Byeong Gwan Kim; Kook Lae Lee Journal: Turk J Gastroenterol Date: 2022-01 Impact factor: 1.555